Market evolution: Other enzymes (CN 350790) — 2015–2025
Introduction
This report analyzes the trade evolution of the European Union in enzymes and prepared enzymes, not elsewhere specified (CN code 350790), from 2015 to 2025. The scope of this code excludes rennet and its concentrates, covering a broad category of industrial and specialty enzymes. Over this period, the EU has solidified its position as a major net exporter, with trade values exhibiting robust growth alongside significant price increases and shifts in regional trade patterns. This analysis delves into the quantitative trends, the underlying market structure, and the dynamics of volatility to provide a comprehensive overview of the sector's performance and its strategic implications for the EU.
Robust Growth Driven by Price Escalation and Expanding Demand
The EU's trade in enzymes displayed strong nominal growth over the period, though the drivers behind exports and imports differed markedly, leading to a strengthened trade surplus.
EU exports surged in value, with price increases outpacing volume growth.
From 2015 to 2025, the value of EU exports of enzymes (CN 350790) grew by 46.2%, rising from €1.49 billion to €2.17 billion. This increase was primarily fueled by a 30.9% rise in export unit prices (from €11,172 to €14,620 per tonne), as physical export volumes saw a more modest growth of 11.7% (from 133,000 to 148,600 tonnes). This indicates a shift towards higher-value enzyme products or general price inflation within the industry.
Import value growth was even stronger, driven almost entirely by higher prices.
EU imports saw an even steeper increase in value, climbing 54.9% from €436 million to €675 million. Unlike exports, this was not a story of rising volumes; import quantities were virtually stagnant, declining slightly by 1.0% to 44,800 tonnes. The entire value increase was therefore attributable to a dramatic 56.7% surge in import unit prices, from €9,595 to €15,033 per tonne.
The EU's trade surplus widened significantly despite rising import costs.
The combination of strong export growth and value-led import growth resulted in a substantial improvement in the EU's trade balance for this product. The surplus expanded by 42.6% over the period, increasing from €1.05 billion in 2015 to €1.50 billion in 2025. The peak surplus was recorded in 2022, reaching nearly €1.70 billion, as shown in the trade overview.
| Metric | 2015 | 2025 | Change (2015-2025) |
|---|---|---|---|
| Export Value (€ bn) | 1.49 | 2.17 | +46.2% |
| Export Volume (kt) | 133.0 | 148.6 | +11.7% |
| Export Price (€/t) | 11,172 | 14,620 | +30.9% |
| Import Value (€ m) | 436 | 675 | +54.9% |
| Import Volume (kt) | 45.3 | 44.8 | -1.0% |
| Import Price (€/t) | 9,595 | 15,033 | +56.7% |
| Trade Balance (€ bn) | 1.05 | 1.50 | +42.6% |
Structural Shifts in Specialization and Trade Partnerships
Beneath the headline growth figures, significant structural changes occurred within the EU's enzyme market, characterized by increasing domestic specialization and evolving partnerships with key global players.
Denmark and the Netherlands dominate EU exports, showcasing high specialization.
The EU's production and export landscape for enzymes is heavily concentrated in a few member states. In 2025, Denmark was by far the largest exporter, with a value of €802 million, followed by Germany (€317 million) and the Netherlands (€403 million). Analysis of revealed comparative advantage (RCA) shows Denmark (RCA of 16.6) and Finland (RCA of 9.8) possess an exceptionally strong specialization in enzyme production, underpinning the EU's competitive edge.
The United States remains the primary bilateral partner, though trade with Asia has grown.
The United States is the EU's most significant trading partner for enzymes, both as a destination for exports (€536 million in 2025) and a source of imports (€307 million). However, the trade partnership with China has deepened considerably, with EU exports to China growing by 39.3% and imports from China doubling (+100.6%). Other notable shifts include a 95.6% increase in exports to Türkiye and a 175.4% surge in exports to India, highlighting growing markets in emerging economies.
UK trade flows were significantly reshaped following Brexit.
A clear discontinuity is visible in trade with the United Kingdom. After a peak in 2020, EU imports of enzymes from the UK fell by 45.7% to €29 million by 2025, while exports to the UK increased by 29.8% to €111 million. This suggests a realignment of supply chains, with the UK becoming a less important supplier to the EU but remaining a vital export market.
EU domestic production expanded strongly, supporting export capacity.
Behind the strong export performance lies substantial growth in EU production volumes. Production quantity increased by 79.9% from 151 to 271 million kg between 2015 and 2025. The production value grew even faster, by 193% to €2.49 billion, indicating a shift to higher-value enzyme formulations.
Volatility, Resilience, and Strategic Market Positioning
The enzyme market experienced periods of volatility, particularly during the post-pandemic recovery, but the EU's overall trade position is characterized by strong resilience and outward orientation.
Price shocks were detected in 2021-2022, particularly in trade with China and India.
The volatility analysis reveals that the most significant price shocks occurred in 2021 and 2022. A major price shock for imports from China in 2021 saw a 25.3% price jump, likely tied to post-COVID-19 supply constraints. Similarly, exports to India experienced a sharp 33.3% price spike in 2021. Trade with the United States, in contrast, has been the most stable (low coefficient of variation), whereas flows with Canada and Mexico have been more volatile.
Import dependence is concentrated, but export diversification is increasing.
The concentration of EU imports has increased, with the Herfindahl-Hirschman Index (HHI) rising from 1,971 to 2,832, indicating a less diversified supplier base increasingly reliant on the US and China. Conversely, export concentration has slightly decreased (HHI falling from 1,029 to 863), showing the EU is successfully spreading its export footprint across a wider range of partners.
The EU demonstrates a strong and growing export propensity for enzymes.
The EU is a clear net exporter in this sector. The net import reliance ratio is deeply negative ( -174% in 2025), meaning exports far exceed imports. More telling, the export propensity—the share of EU production that is exported—has increased from 77% to 88%. This indicates the EU enzyme industry is globally oriented and highly competitive, with production growth tightly linked to international demand.
Conclusion
Between 2015 and 2025, the EU's enzyme market (CN 350790) experienced strong nominal growth, driven by significant price inflation and solidifying its position as a major global exporter. While import costs rose sharply, the EU's robust export performance, led by specialized producers in Northern Europe, resulted in a 43% expansion of its trade surplus. The market structure evolved, with post-Brexit trade shifts and growing ties with Asian economies. Despite experiencing price shocks during global supply disruptions, the EU's strategic position remains strong, characterized by high export propensity, expanding domestic production, and a successful, if slightly more diversified, export portfolio. The sector exemplifies a high-value, globally integrated industry where the EU holds a competitive advantage.